Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · Potential pulmonary fibrosis therapy CAL101 fares well in study. CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in ...
MNKD-201, inhaled nintedanib for IPF, found safe in Phase 1 trial
5 hours ago · by Andrea Lobo November 15, 2024. MNKD-201, Mannkind ’s inhaled formulation of nintedanib for treating idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers — meeting the study’s primary goal. The trial’s results also showed that participants did not ...
New prototype therapy may repair IPF lung scarring by …
by Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Now you know: Updates from my journey living with IPF November 5, 2024; My increasing interest in my family medical history October 29, 2024; Researchers will team up to develop pulmonary fibrosis stem cell models October 25, 2024; Keeping track of meds is part of my post-transplant plan October 22, 2024; Pro-fibrotic immune cell detected in lungs of long COVID-19 patients ...
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
by Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
Bexotegrast reverses signs of IPF lung scarring in Phase 2a trial
by Steve Bryson, PhD May 17, 2024. Pliant Therapeutics ’ bexotegrast reversed the signs of lung scarring, while improving lung function and easing cough severity in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a small Phase 2a imaging trial. Using positron emission tomography (PET) scans, researchers at ...
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
Apr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
Apr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
Oct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also ...